Mechanisms of allergy and clinical immunologySalmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease by modulating protein phosphatase 2A
Section snippets
Methods
For more detailed methods, see the Methods section in this article's Online Repository at www.jacionline.org.
Systemic salmeterol suppresses HDM-induced AHR and inflammation but not numbers of PAS-positive cells
We administered salmeterol or vehicle control intraperitoneally 24 hours before and during the challenge phase in a mouse model of HDM-induced AAD (see Fig E1, A). Data collection was performed 24 hours after the last salmeterol administration to account for possible bronchodilator effects influencing airways resistance. This was based on the documented duration of action of salmeterol in human subjects,29 as well as our own data from time course studies in naive mice showing protective effects
Discussion
Using a well-characterized model of HDM-induced AAD,26, 27 we observed suppression of AHR, as well as reduced eosinophilic airways inflammation, caused by systemic and local salmeterol treatment, whereas blood eosinophil levels mildly increased. This suggests that the anti-inflammatory effect of salmeterol might be associated with impaired eosinophilic chemotaxis rather than proliferation or maturation. This was supported by reduced levels of CCL11, which is crucial for eosinophil tissue homing,
References (47)
- et al.
The interplay of dendritic cells, Th2 cells and regulatory T cells in asthma
Curr Opin Immunol
(2004) The role of eosinophils in the pathogenesis of asthma
Trends Mol Med
(2005)Immunologic and inflammatory mechanisms that drive asthma progression to remodeling
J Allergy Clin Immunol
(2008)- et al.
Biology of lung dendritic cells at the origin of asthma
Immunity
(2009) The global burden of asthma
Chest
(2006)- et al.
Asthma exacerbations: origin, effect, and prevention
J Allergy Clin Immunol
(2011) - et al.
The role of rhinovirus in asthma exacerbations
J Allergy Clin Immunol
(2005) From the page to the clinic: implementing new National Asthma Education and Prevention Program guidelines
Clin Cornerstone
(2009)New therapies for asthma: is there any progress?
Trends Pharmacol Sci
(2010)- et al.
Effects of dual therapy with corticosteroids plus long acting beta2-agonists in asthma
Respir Med
(2005)
Increased corticosteroid sensitivity by a long acting beta(2) agonist formoterol via beta(2) adrenoceptor independent protein phosphatase 2A activation
Pulm Pharmacol Ther
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues
J Biol Chem
Severe asthma: advances in current management and future therapy
J Allergy Clin Immunol
Okadaic acid induces sustained activation of NFkappaB and degradation of the nuclear IkappaBalpha in human neutrophils
Arch Biochem Biophys
New treatment regimes for virus-induced exacerbations of asthma
Pulm Pharmacol Ther
Oral prednisone therapy in experimental rhinovirus infections
J Allergy Clin Immunol
The common cold: effects of intranasal fluticasone propionate treatment
J Allergy Clin Immunol
Allergy and allergic diseases. First of two parts
N Engl J Med
Chemokines in allergic lung inflammation
Immunology
The role of the airway epithelium and its interaction with environmental factors in asthma pathogenesis
Proc Am Thorac Soc
Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease
Nat Med
Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma
Clin Exp Allergy
Sensitivity of respiratory virus culture when screening with R-mix fresh cells
J Clin Microbiol
Cited by (0)
Supported by the National Health Medical Research Council (NH&MRC; G1000314 to J.M. and N.V.) and an NH&MRC Health Professional Research Fellowship (G0186769 to J.M.). S.L.J. was supported by a Chair from Asthma UK (CH1155). This work was supported in part by MRC Centre Grant G1000758 and ERC FP7 Advanced Grant 233015 (to S.L.J.).
Disclosure of potential conflict of interest: N. Verrills has received research support from the NH&MRC (grant no. G1000314). S. L. Johnston has received research support from a Chair from Asthma UK (Ch1155), the Medical Research Council (grant no. G1000758), and the European Research Council (FP7 advanced grant G233015); has received consultancy fees from Centocor, Sanofi Pasteur, Synairgen, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Grünenthal, and Novartis; has patents planned, pending, or issued (UK patent application no. 02 167 29.4 and International patent application no. PCT/EP2003/007939; UK patent application no. GB 0405634.7; UK patent application no. 0518425.4); and has stock/stock options in Synairgen. J. Mattes has received research support from the National Health and Medical Research Council (NH&MRC; grant no. G1000314) and an NH&MRC Health Professional Research Fellowship (GO186769). The rest of the authors declare that they have no relevant conflicts of interest.